Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year study
Type 2 Diabetes Mellitus (T2DM) yields high cardiovascular morbidity, resulting in overwhelming healthcare costs. We investigated whether the combined administration of the cardioprotective agent Glucagon-Like Peptide-1 receptor agonists (GLP1-RA) liraglutide and Sodium-Glucose Cotransporter-2 Inhibitor (S...